Main cytogenetic characteristics according to cytogenetic subgroups
| Cytogenetic subgroup . | Cases, N . | Abnormal karyotype, N (%) . | Median MNC . | Chromosome gains, N (%) . | Chromosome losses, N (%) . | Structural CA, N (%) . | Deletions,* N (%) . | Additional CA, N (%) . | Median CA, N (range) . | Complex karyotype, N (%) . | Monosomal karyotype, N (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 542 | 388 (72) | 46 | 180 (33) | 102 (19) | 338 (62) | 133 (25) | 237 (44) | 1 (1-26) | 27 (5) | 82 (15) |
| Primary subgroups | |||||||||||
| t(4;11)(q21;q23) | 72 | 69 (96) | 46 | 25 (35) | 4 (6) | 72 (100) | 8 (11) | 30 (42) | 1 (1-13) | NA | 4 (6) |
| Other t(v;11q23) | 11 | 9 (82) | 46 | 4 (36) | 1 (9) | 11 (100) | 1 (9) | 5 (45) | 2 (1-11) | NA | 4 (6) |
| t(1;19)(q23;p13) | 28 | 26 (93) | 46 | 5 (18) | 5 (18) | 28 (100) | 13 (46) | 17 (61) | 3 (1-7) | NA | 2 (7) |
| Ho-Tr | 33 | 30 (91) | 36-69 | 6 (18) | 33 (100) | 15 (45) | 1 (3) | 21 (45) | NA | NA | 33 (100) |
| HeH | 36 | 32 (89) | 56 | 36 (100) | 5 (14) | 21 (58) | 9 (25) | 23 (64) | NA | NA | 4 (11) |
| ETV6-RUNX1 | 2 | 1 | 52 | 1 | 0 | 2 | 0 | 1 | 11 | NA | 0 |
| iAMP21 | 3 | 3 | 47 | 3 | 1 | 3 | 0 | 3 | 3 (2-10) | 1 | 1 |
| 14q32/IGH | 27 | 27 (100) | 46 | 16 (59) | 8 (30) | 27 (100) | 10 (37) | 22 (81) | 3 (1-20) | NA | 6 (22) |
| Other abnormalities | 210 | 191 (91) | 46 | 84 (40) | 46 (22) | 159 (76) | 91 (43) | 115 (55) | 2 (1-26) | 26 (12) | 31 (15) |
| Secondary subgroups | |||||||||||
| Complex karyotypes | 27 | 27 (100) | 46 | 23 (85) | 21 (78) | 26 (96) | 18 (67) | 27 (100) | 6 (5-12) | 27 (100) | 21 (78) |
| Monosomal karyotypes | 82† | 79 (96) | 46 | 47 (57) | 82 (100) | 61 (74) | 30 (37) | 79 (96) | 6 (2-26) | 21 (26) | 82 (100) |
| Cytogenetic subgroup . | Cases, N . | Abnormal karyotype, N (%) . | Median MNC . | Chromosome gains, N (%) . | Chromosome losses, N (%) . | Structural CA, N (%) . | Deletions,* N (%) . | Additional CA, N (%) . | Median CA, N (range) . | Complex karyotype, N (%) . | Monosomal karyotype, N (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 542 | 388 (72) | 46 | 180 (33) | 102 (19) | 338 (62) | 133 (25) | 237 (44) | 1 (1-26) | 27 (5) | 82 (15) |
| Primary subgroups | |||||||||||
| t(4;11)(q21;q23) | 72 | 69 (96) | 46 | 25 (35) | 4 (6) | 72 (100) | 8 (11) | 30 (42) | 1 (1-13) | NA | 4 (6) |
| Other t(v;11q23) | 11 | 9 (82) | 46 | 4 (36) | 1 (9) | 11 (100) | 1 (9) | 5 (45) | 2 (1-11) | NA | 4 (6) |
| t(1;19)(q23;p13) | 28 | 26 (93) | 46 | 5 (18) | 5 (18) | 28 (100) | 13 (46) | 17 (61) | 3 (1-7) | NA | 2 (7) |
| Ho-Tr | 33 | 30 (91) | 36-69 | 6 (18) | 33 (100) | 15 (45) | 1 (3) | 21 (45) | NA | NA | 33 (100) |
| HeH | 36 | 32 (89) | 56 | 36 (100) | 5 (14) | 21 (58) | 9 (25) | 23 (64) | NA | NA | 4 (11) |
| ETV6-RUNX1 | 2 | 1 | 52 | 1 | 0 | 2 | 0 | 1 | 11 | NA | 0 |
| iAMP21 | 3 | 3 | 47 | 3 | 1 | 3 | 0 | 3 | 3 (2-10) | 1 | 1 |
| 14q32/IGH | 27 | 27 (100) | 46 | 16 (59) | 8 (30) | 27 (100) | 10 (37) | 22 (81) | 3 (1-20) | NA | 6 (22) |
| Other abnormalities | 210 | 191 (91) | 46 | 84 (40) | 46 (22) | 159 (76) | 91 (43) | 115 (55) | 2 (1-26) | 26 (12) | 31 (15) |
| Secondary subgroups | |||||||||||
| Complex karyotypes | 27 | 27 (100) | 46 | 23 (85) | 21 (78) | 26 (96) | 18 (67) | 27 (100) | 6 (5-12) | 27 (100) | 21 (78) |
| Monosomal karyotypes | 82† | 79 (96) | 46 | 47 (57) | 82 (100) | 61 (74) | 30 (37) | 79 (96) | 6 (2-26) | 21 (26) | 82 (100) |